Evaluation of Topical Liposomal Lidocaine and Oral Sucrose for Treatment of Pain in Newborns Undergoing Venipuncture

NCT ID: NCT00519207

Last Updated: 2011-07-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

330 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-08-31

Study Completion Date

2009-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to determine the relative efficacy of sucrose, liposomal lidocaine, and sucrose plus liposomal lidocaine, on reducing pain during venipuncture in newborn infants.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Despite the fact that modern medical practice is greatly advanced, pain is inflicted on all Canadian newborn infants in the first days and months of life from blood tests, injections and cannulations designed to prevent, diagnose or manage medical conditions. Procedural pain in newborn infants is a significant burden to infants, their parents, healthcare workers, and society at large.

This study proposes a large randomized controlled trial to determine the optimal analgesic regimen for procedural pain using methods that can be easily implemented in clinical practice. We will study liposomal lidocaine cream and sucrose oral liquid, used alone, or together, to manage procedural pain. Liposomal lidocaine is a relatively new anaesthetic formulation ideally suited for young infants due to the established role of lidocaine in neonatal clinical medicine. Sucrose (sugar water) reduces pain responses and is promoted in consensus guidelines developed by pain experts. However, it is perceived by many front-line clinicians to be simply a comforting agent rather than a true analgesic. Studying liposomal lidocaine and sucrose together is important since the combination may prove superior to either agent alone, and may even prevent or abolish pain from clinical procedures.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

This group will receive lidocaine and sucrose placebo (water).

Group Type ACTIVE_COMPARATOR

Lidocaine

Intervention Type DRUG

1g of liposomal lidocaine will be administered 30-40 minutes prior to venipuncture and occluded by a dressing.

2

This group will receive lidocaine placebo and sucrose.

Group Type ACTIVE_COMPARATOR

24% Sucrose Solution

Intervention Type DRUG

2ml of 24% sucrose will be administered 2 minutes prior to venipuncture

3

This group will receive lidocaine and sucrose.

Group Type ACTIVE_COMPARATOR

Lidocaine

Intervention Type DRUG

1g of liposomal lidocaine will be administered 30-40 minutes prior to venipuncture and occluded by a dressing.

24% Sucrose Solution

Intervention Type DRUG

2ml of 24% sucrose will be administered 2 minutes prior to venipuncture

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Lidocaine

1g of liposomal lidocaine will be administered 30-40 minutes prior to venipuncture and occluded by a dressing.

Intervention Type DRUG

24% Sucrose Solution

2ml of 24% sucrose will be administered 2 minutes prior to venipuncture

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Maxilene 4 TootSweet

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy newborn infants
* ≥ 37 weeks gestational age.

Exclusion Criteria

* neonatal intensive care unit (NICU) admission
* asphyxia, seizures
* major birth defect (heart, brain, genetic syndrome)
* circumcised during study
* receiving analgesia/sedatives.
Minimum Eligible Age

1 Day

Maximum Eligible Age

7 Days

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

Sponsor Role collaborator

The Hospital for Sick Children

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

The Hospital for Sick Children

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Anna Taddio, PhD

Role: PRINCIPAL_INVESTIGATOR

The Hospital for Sick Children, Toronto Canada

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Mount Sinai Hospital

Toronto, Ontario, Canada

Site Status

The Hospital for Sick Children

Toronto, Ontario, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

1000010747

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Efficacy of a New Topical Anesthetic
NCT00562211 COMPLETED PHASE1/PHASE2